FAKTOR-OPTIONSSCHEIN - GENMAB Stock

Certificat

DE000SB26YB8

Market Closed - Deutsche Boerse AG 15:44:44 2024-06-14 EDT
0.25 EUR -3.85% Intraday chart for FAKTOR-OPTIONSSCHEIN - GENMAB
Current month+19.05%
1 month+31.58%
Date Price Change
24-06-14 0.25 -3.85%
24-06-13 0.26 +4.00%
24-06-12 0.25 +8.70%
24-06-11 0.23 +4.55%
24-06-10 0.22 0.00%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 03:44 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying GENMAB A/S
IssuerLogo Issuer Société Générale Société Générale
WKN SB26YB
ISINDE000SB26YB8
Date issued 2020-07-21
Strike 2,324 kr
Maturity Unlimited
Parity 1 : 1
Emission price 1.36
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.67
Lowest since issue 0.085
Spread 0.01
Spread %3.85%

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Sector
-
More about the company

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Genmab A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832 DKK
Average target price
2,464 DKK
Spread / Average Target
+34.46%
Consensus